Literature DB >> 25669950

[Risk factors for tardive movement disorders in schizophrenia].

D E Tenback, P R Bakker, P N van Harten.   

Abstract

BACKGROUND: Tardive movement disorders are common among patients with schizophrenia. Risk factors for movement disorders are of the utmost importance in the context of preventive strategies. AIM: To achieve clearer classification of movement disorders in schizophrenia, to identify the risk factors involved and thereby develop strategies to prevent movement disorders.
METHOD: We searched PubMed for prospective studies which had been performed in homogeneous target populations with schizophrenia and which contained well-defined definitions of the movement disorders. From these we selected studies in which risk factors were repeatedly identified.
RESULTS: Tardive dyskinesia is well documented. Risk factors for developing tardive dyskinesia are use of antipsychotics, particularly those belonging to the first generation, 'not belonging to the Caucasian race', early extrapyramidal symptoms and older age. So far, there is very little conclusive evidence regarding the genetics of tardive movement disorders.
CONCLUSION: With regard to tardive dyskinesia, not belonging to the Caucasian race and old age are two risk factors that can be quickly determined for the purpose of prevention. In this case it leads to the choice of medication with a low D2 affinity. Furthermore, it is advisable, after commencing treatment with an antipsychotic drug, to evaluate on a regular basis if the patient is showing (early) signs of TD. If TD does occur, there is a choice between medication with a low D-2 affinity or clozapine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25669950

Source DB:  PubMed          Journal:  Tijdschr Psychiatr        ISSN: 0303-7339


  4 in total

Review 1.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

Review 2.  Tardive Dyskinesia: Treatment Update.

Authors:  Divya Arya; Tarannum Khan; Adam J Margolius; Hubert H Fernandez
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-16       Impact factor: 5.081

Review 3.  Tardive Dyskinesia in Older Persons Taking Antipsychotics.

Authors:  Leslie Citrome; Stuart H Isaacson; Danielle Larson; Daniel Kremens
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-14       Impact factor: 2.570

4.  Impact of a pharmacist-driven tardive dyskinesia screening service.

Authors:  Niyati Butala; Andrew Williams; Jamie Kneebusch; Melissa Mitchell
Journal:  Ment Health Clin       Date:  2021-07-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.